Lactic acid bacteria strains useful against urogenital pathogens and compositions containing same

Abstract

The invention relates to a method for preventing or treating urogenital infections in females, which comprises administering a pharmaceutical preparation comprising, in combination with a suitable galenical carrier, a therapeutically effective amount of at least one lactic acid bacteria strain of the genus L. acidophilus, L. crispatus, L. gasseri, L. helveticus and L. jensenii selected for their ability to kill urogenital and/or gastrointestinal pathogens and their ability to inhibit internalization of urogenital and/or gastrointestinal pathogens within vaginal epithelial cells, as well as for their ability to modulate a humoral and/or cellular immune response at the vaginal and/or gastrointestinal level, in particular to inhibit the inflammatory syndrome as well as the infectious syndrome.

1 . A method for treating urogenital infections in females which comprises administering to a female in need of such treatment a pharmaceutical preparation comprising a therapeutically effective amount of at least one lactic acid bacteria strain selected from the group consisting of  L. crispatus  KS 116.1 (CNCM 1-3483),  L. crispatus  KS 119.4 (CNCM 1-3484),  L. crispatus  127.1 (CNCM 1-3486),  L. gasseri  KS 114.1 (CNCM 1-3482),  L. gasseri  KS 120.1 (CNCM 1-3218),  L. gasseri  KS 123.1 (CNCM 1-3485),  L. gasseri  KS 124.3 (CNCM 1-3220),  L. helveticus  KS 300 (CNCM 1-3360),  L. jensenii  KS 119.1 (CNCM 1-3217) and  L. jensenii  KS 121.1 (CNCM 1-3219) in combination with a pharmaceutically acceptable galenical carrier.  
     
     
         2 . The method of  claim 1  wherein the galenical carrier is designed for local administration.  
     
     
         3 . The method of  claim 1  wherein the galenical carrier is designed for oral administration.  
     
     
         4 . A method for inhibiting adhesion, colonization and/or growth of pathogeris in the urogenital tract of females which comprises administering to a female in need of such treatment a pharmaceutical preparation comprising a therapeutically effective amount of at least one lactic acid bacteria strain selected from the group consisting of  L. crispatus  KS 116.1 (CNCM 1-3483),  L. crispatus  KS 119.4 (CNCM 1-3484),  L. crispatus  127.1 (CNCM 1-3486),  L. gasseri  KS 114.1 (CNCM 1-3482),  L. gasseri  KS 120.1 (CNCM 1-3218),  L. gasseri  KS 123.1 (NCM 1-3485),  L. gasseri  KS 124.3 (NCM 1-3220),  L. helveticus  KS 300 (CNCM 1-3360),  L. jensenii  KS 119.1 (CNCM 1-3217) and  L. jensenii  KS 121.1 (CNCM 1-3219) in combination with a pharmaceutically acceptable galenical carrier.  
     
     
         5 . The method of  claim 4  wherein the galenical carrier is designed for local administration.  
     
     
         6 . The method of  claim 4  wherein the galenical carrier is designed for oral administration.  
     
     
         7 . Lactic acid bacteria strains selected from-the group consisting of  L. crispatus  KS 116.1 (CNCM 1-3483),  L. crispatus  KS 119.4 (CNCM 1-3484),  L. crispatus  127.1 (CNCM 1-3486),  L. gasseri  KS 114.1 (CNCM 1-3482),  L. gasseri  KS 120.1 (CNCM 1-3218),  L. gasseri  KS 123.1 (CNCM 1-3485),  L. gasseri  KS 124.3 (CNCM 1-3220),  L. helveticus  KS 300 (CNCM 1-3360),  L. jensenii  KS 119.1 (CNCM 1-3217) and  L. jensenii  KS 121. 1 (CNCM 1-3219).